| Filed | As-Of/On | Form | Fullname | Symbol | Country | Industry | Shares | Activity | Shares Change | Shares Pct. Change | Hypothetical Old Value | Hypothetical New Value | Hypothetical Value Chg. | Hypothetical Return | Hypothetical Results |
Director |
Other |
Ten Pct |
Officer |
Officer Title |
News Article |
History |
|---|
| 2009-08-27 | 2009-06-30 | N-CSRS | Roche Holding Ag | RHHBY.OB | CH | Medical-Drugs | 4,346 | Sold Some | -826 | -15.97 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Roche Holding Ag |
| 2009-08-27 | 2009-06-30 | N-CSRS | Bayer Ag | BAYZF.OB | US | Chemicals-Diversified | 6,088 | Sold Some | -1,611 | -20.92 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Bayer Ag |
| 2009-08-27 | 2009-06-30 | N-CSRS | Reckitt Benckiser Group Plc | RBGPF.OB | GB | Soap And Cleaning Prepar | 2,498 | Sold Some | -281 | -10.11 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Reckitt Benckiser Group Plc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Amag Pharmaceuticals Inc | AMAG | BE | Medical-Biomedical/Gene | 4,197 | Sold Some | -1,978 | -32.03 % | $174,889 | $166,831 | $-8,058 | -4.60 % | $3,798 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Amag Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Thermo Fisher Scientific Inc | TMO | US | Instruments-Scientific | 4,015 | Added More | 1,957 | 95.09 % | $182,683 | $186,938 | $4,256 | 2.32 % | $2,074 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Thermo Fisher Scientific Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Incyte Corp Ltd | INCY | US | Medical-Biomedical/Gene | 0 | Sold All | -23,821 | -100 % | - | - | - | 17.60 % | $-26,918 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Incyte Corp Ltd |
| 2009-08-27 | 2009-06-30 | N-CSRS | Genoptix Inc | GXDX | US | Medical Labs And Testing Srv | 2,450 | New Holding | 2,450 | 100 % | $71,320 | $89,327 | $18,008 | 25.24 % | $18,008 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Genoptix Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Human Genome Sciences Inc | HGSI | US | Medical-Biomedical/Gene | 19,743 | Sold Some | -7,198 | -26.71 % | $374,327 | $540,563 | $166,236 | 44.40 % | $-60,607 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Human Genome Sciences Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Alexion Pharmaceuticals Inc | ALXN | US | Medical-Biomedical/Gene | 9,636 | Added More | 744 | 8.36 % | $430,344 | $421,093 | $-9,251 | -2.14 % | $-714 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Alexion Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Array Biopharma Inc | ARRY | US | Medical-Drugs | 12,342 | Sold Some | -924 | -6.96 % | $50,602 | $25,054 | $-25,548 | -50.48 % | $1,913 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Array Biopharma Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Acorda Therapeutics Inc | ACOR | US | Medical-Biomedical/Gene | 8,304 | Sold Some | -1,609 | -16.23 % | $191,988 | $198,466 | $6,477 | 3.37 % | $-1,255 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Acorda Therapeutics Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Auxilium Pharmaceuticals Inc | AUXL | US | Medical-Drugs | 5,439 | Added More | 128 | 2.41 % | $153,815 | $189,984 | $36,169 | 23.51 % | $851 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Auxilium Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Biomarin Pharmaceutical Inc | BMRN | US | Therapeutics | 0 | Sold All | -4,473 | -100 % | - | - | - | 5.60 % | $-4,026 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Biomarin Pharmaceutical Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Stryker Corp | SYK | US | Medical Products | 5,574 | Added More | 2,024 | 57.01 % | $230,875 | $271,621 | $40,746 | 17.64 % | $14,795 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Stryker Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Forest Laboratories Inc | FRX | US | Medical-Drugs | 8,876 | Sold Some | -675 | -7.06 % | $259,090 | $262,463 | $3,373 | 1.30 % | $-257 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Forest Laboratories Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Astrazeneca Plc | AZN | IT | Medical-Drugs | 8,130 | New Holding | 8,130 | 100 % | $380,403 | $364,387 | $-16,016 | -4.21 % | $-16,016 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Astrazeneca Plc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Baxter International Inc | BAX | US | Medical Products | 5,818 | Added More | 408 | 7.54 % | $330,579 | $316,092 | $-14,487 | -4.38 % | $-1,016 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Baxter International Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Mylan Incpa | MYL | US | Medical-Generic Drugs | 8,198 | Sold Some | -8,994 | -52.31 % | $121,986 | $143,875 | $21,889 | 17.94 % | $-24,014 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Mylan Incpa |
| 2009-08-27 | 2009-06-30 | N-CSRS | Humana Inc | HUM | US | Medical-Hmo | 4,499 | Sold Some | -1,479 | -24.74 % | $166,553 | $181,940 | $15,387 | 9.23 % | $-5,058 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Humana Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Theravance Inc | THRX | US | Therapeutics | 5,603 | Sold Some | -873 | -13.48 % | $89,480 | $78,666 | $-10,814 | -12.08 % | $1,685 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Theravance Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Covidien Ltd | COV | BM | Medical Products | 8,008 | Sold Some | -4 | -0.04 % | $312,312 | $365,565 | $53,253 | 17.05 % | $-27 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Covidien Ltd |
| 2009-08-27 | 2009-06-30 | N-CSRS | Glaxosmithkline Plc | GSK | IT | Medical-Drugs | 7,263 | Added More | 2,183 | 42.97 % | $287,470 | $301,632 | $14,163 | 4.92 % | $4,257 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Glaxosmithkline Plc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Xenoport Inc | XNPT | US | Medical-Drugs | 9,956 | Added More | 2,656 | 36.38 % | $179,507 | $162,781 | $-16,726 | -9.31 % | $-4,462 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Xenoport Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Sequenom Inc | SQNM | US | Medical-Biomedical/Gene | 0 | Sold All | -12,252 | -100 % | - | - | - | -41.82 % | $27,567 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Sequenom Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Onyx Pharmaceuticals Inc | ONXX | US | Therapeutics | 7,641 | Added More | 464 | 6.46 % | $241,226 | $213,872 | $-27,355 | -11.33 % | $-1,661 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Onyx Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Bristol-Myers Squibb Co | BMY | BE | Medical-Drugs | 9,411 | Added More | 902 | 10.60 % | $214,383 | $230,193 | $15,810 | 7.37 % | $1,515 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Bristol-Myers Squibb Co |
| 2009-08-27 | 2009-06-30 | N-CSRS | Becton Dickinson And Co | BDX | US | Medical Products | 2,213 | New Holding | 2,213 | 100 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Becton Dickinson And Co |
| 2009-08-27 | 2009-06-30 | N-CSRS | Alcon Inc | ACL | CH | Optical Supplies | 2,239 | Added More | 335 | 17.59 % | $292,593 | $325,237 | $32,645 | 11.15 % | $4,884 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Alcon Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Sanofi-Aventis Sa | SNY | FR | Medical-Drugs | 0 | Sold All | -2,809 | -100 % | - | - | - | 10.08 % | $-9,691 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Sanofi-Aventis Sa |
| 2009-08-27 | 2009-06-30 | N-CSRS | Alexandria Real Estate Equities Inc | ARE | US | Reits-Office Property | 0 | Sold All | -1,075 | -100 % | - | - | - | 6.25 % | $-3,634 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Alexandria Real Estate Equities Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Pharmstandard Ojsc | 70SK.L | US | Medical-Generic Drugs | 5,429 | Sold Some | -3,446 | -38.82 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Pharmstandard Ojsc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Osi Pharmaceuticals Inc | OSIP | US | Medical-Drugs | 6,322 | Added More | 834 | 15.19 % | $217,097 | $207,298 | $-9,799 | -4.51 % | $-1,293 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Osi Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Cvscaremark Corp | CVS | US | Retail-Drug Store | 14,083 | New Holding | 14,083 | 100 % | $518,818 | $445,586 | $-73,232 | -14.11 % | $-73,232 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Cvscaremark Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Celgene Corp | CELG | US | Medical-Biomedical/Gene | 12,830 | Added More | 1,921 | 17.60 % | $686,790 | $704,495 | $17,705 | 2.57 % | $2,651 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Celgene Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Genzyme Corp | GENZ | US | Medical-Biomedical/Gene | 8,877 | Added More | 2,126 | 31.49 % | $505,101 | $444,294 | $-60,807 | -12.03 % | $-14,563 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Genzyme Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Gilead Sciences Inc | GILD | US | Therapeutics | 10,619 | Sold Some | -568 | -5.07 % | $486,563 | $492,615 | $6,053 | 1.24 % | $-324 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Gilead Sciences Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Martek Biosciences Corp | MATK | US | Medical-Biomedical/Gene | 3,274 | Sold Some | -1,716 | -34.38 % | $82,799 | $59,292 | $-23,507 | -28.39 % | $12,321 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Martek Biosciences Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Intuitive Surgical Inc | ISRG | US | Medical Instruments | 1,340 | Sold Some | -826 | -38.13 % | $302,585 | $370,430 | $67,844 | 22.42 % | $-41,820 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Intuitive Surgical Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Myriad Genetics Inc | MYGN | US | Medical-Biomedical/Gene | 4,770 | Added More | 1,027 | 27.43 % | $144,388 | $112,572 | $-31,816 | -22.03 % | $-6,850 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Myriad Genetics Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Hospira Inc | HSP | US | Drug Delivery Systems | 4,111 | Sold Some | -803 | -16.34 % | $165,057 | $192,724 | $27,667 | 16.76 % | $-5,404 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Hospira Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Johnson And Johnson | JNJ | US | Medical Products | 3,808 | Sold Some | -22 | -0.57 % | $230,346 | $237,276 | $6,931 | 3.00 % | $-40 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Johnson And Johnson |
| 2009-08-27 | 2009-06-30 | N-CSRS | United Therapeutics Corp | UTHR | US | Therapeutics | 3,173 | Added More | 182 | 6.08 % | $289,378 | $142,499 | $-146,878 | -50.75 % | $-8,425 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of United Therapeutics Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Medco Health Solutions Inc | MHS | US | Pharmacy Services | 5,245 | Sold Some | -1,192 | -18.51 % | $292,356 | $323,144 | $30,788 | 10.53 % | $-6,997 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Medco Health Solutions Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Novartis Ag | NVS | CH | Medical-Drugs | 5,398 | Sold Some | -219 | -3.89 % | $251,709 | $286,796 | $35,087 | 13.93 % | $-1,424 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Novartis Ag |
| 2009-08-27 | 2009-06-30 | N-CSRS | Arena Pharmaceuticals Inc | ARNA | US | Medical-Biomedical/Gene | 14,329 | Sold Some | -1,059 | -6.88 % | $68,206 | $50,295 | $-17,911 | -26.26 % | $1,324 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Arena Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Monsanto Co | MON | US | Agricultural Chemicals | 1,418 | New Holding | 1,418 | 100 % | $119,991 | $113,553 | $-6,438 | -5.36 % | $-6,438 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Monsanto Co |
| 2009-08-27 | 2009-06-30 | N-CSRS | Tomotherapy Inc | TTPY | KY | Medical Products | 17,406 | Sold Some | -3,725 | -17.62 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Tomotherapy Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Savient Pharmaceuticals Inc | SVNT | US | Medical-Biomedical/Gene | 4,618 | Sold Some | -5,726 | -55.35 % | $63,498 | $63,775 | $277 | 0.43 % | $-344 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Savient Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Vertex Pharmaceuticals Inc | VRTX | US | Medical-Biomedical/Gene | 5,389 | New Holding | 5,389 | 100 % | $201,387 | $207,692 | $6,305 | 3.13 % | $6,305 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Vertex Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Shire Plc | SHPGY | DE | Medical-Drugs | 3,664 | Sold Some | -688 | -15.80 % | $184,885 | $206,760 | $21,874 | 11.83 % | $-4,107 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Shire Plc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Unitedhealth Group Inc | UNH | US | Medical-Hmo | 14,467 | Sold Some | -2,269 | -13.55 % | $418,675 | $413,178 | $-5,497 | -1.31 % | $862 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Unitedhealth Group Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Abbott Laboratories | ABT | US | Medical-Drugs | 8,371 | Added More | 2,461 | 41.64 % | $390,172 | $449,020 | $58,848 | 15.08 % | $17,301 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Abbott Laboratories |
| 2009-08-27 | 2009-06-30 | N-CSRS | Cougar Biotechnology Inc | CGRB | US | Medical-Biomedical/Gene | 0 | Sold All | -3,244 | -100 % | - | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Cougar Biotechnology Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Coventry Health Care Inc | CVH | US | Medical-Hmo | 0 | Sold All | -9,048 | -100 % | - | - | - | -0.96 % | $1,991 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Coventry Health Care Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Amgen Inc | AMGN | US | Medical-Biomedical/Gene | 4,931 | Added More | 20 | 0.40 % | $297,093 | $273,079 | $-24,014 | -8.08 % | $-97 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Amgen Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Zimmer Holdings Inc | ZMH | US | Medical Products | 0 | Sold All | -2,664 | -100 % | - | - | - | 17.21 % | $-22,271 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Zimmer Holdings Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Medtronic Inc | MDT | US | Medical Instruments | 4,188 | Added More | 139 | 3.43 % | $163,248 | $165,929 | $2,680 | 1.64 % | $89 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Medtronic Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Wyeth | WYE | US | Medical-Drugs | 10,614 | Sold Some | -251 | -2.31 % | $510,640 | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Wyeth |
| 2009-08-27 | 2009-06-30 | N-CSRS | St Jude Medical Inc | STJ | US | Medical Instruments | 7,006 | Added More | 342 | 5.13 % | $272,323 | $240,446 | $-31,877 | -11.70 % | $-1,556 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of St Jude Medical Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Schering-Plough Corp | SGP | US | Medical-Drugs | 12,015 | Sold Some | -208 | -1.70 % | $340,385 | - | - | - % | | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Schering-Plough Corp |
| 2009-08-27 | 2009-06-30 | N-CSRS | Achillion Pharmaceuticals Inc | ACHN | US | Medical-Drugs | 20,749 | Sold Some | -1,516 | -6.80 % | $38,801 | $39,838 | $1,037 | 2.67 % | $-76 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Achillion Pharmaceuticals Inc |
| 2009-08-27 | 2009-06-30 | N-CSRS | Pfizer Inc | PFE | US | Medical-Drugs | 16,610 | Added More | 3,840 | 30.07 % | $280,045 | $304,960 | $24,915 | 8.89 % | $5,760 | | | | | | News Article | History of Janus Aspen Series - Global Life Sciences Portfolio Ownership Of Pfizer Inc |
![]() |
| |
Note: All amounts are based on price of stock at date reported versus the current price! They do not represent actual profit/loss! There has been no adjustmentsfor splits! |
| Note: All amounts in USD, converted using Intrabank Exchange Rate on Date Reported/Today |
|
Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice, and may be inaccurate!
|
| Note: For security reasons, only (A-Z,a-z,0-9,space,period,colon,comma,forward slash,at) can be inputed - all others are stripped automatically! |
|
Copyright © 2007 All rights reserved. Please see our Terms of Use.
|
|
![]() |